Fulcrum Therapeutics, Inc. Stock News

The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise

Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript

Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.50 per share a year ago.

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alex Sapir - President and Chief Exe

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to

Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcrum's sickle-cell disease candidate, allowing the c

CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.

Fulcrum Therapeutics Inc (NASDAQ:FULC) is up 49.7% to trade at $5.87 at last glance -- its highest levels since March -- after the U.S. Food and Drug Administration (FDA) lifted its clinical hold on t

Fulcrum Therapeutics (NASDAQ: FULC ) stock is on the rise Tuesday as investors react to positive news from the FDA. The big news here is the FDA lifted its clinical hold on the Investigational New Dru

Fulcrum Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its sickle cell disease therapeutic F

Fulcrum Utility Services Ltd (AIM:FCRM), the energy infrastructure group, shed more than two-thirds of its value on Monday after it announced it would be cancelling its AIM listing subject to sharehol

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alexander Sapir - President and Chief

Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.83 per share a year ago.